ABSTRACT
Lenacapavir (LEN), the first‐in‐class HIV‐1 capsid inhibitor (CAI) with picomolar potency and long pharmacokinetics (PK), is approved for both treatment and pre‐exposure prophylaxis (PrEP). However, the frequently selected M66I mutation confers complete resistance to LEN. Potent antivirals against the M66I variant remain elusive. In this work, we have designed LEN analogs featuring a distinctive R 2 moiety to directly address the molecular mechanism of resistance. Our analog synthesis also entailed developing a new synthetic procedure for R 2 incorporation. Significantly, the newly designed analogs were highly potent against both WT HIV‐1 and the M66I mutant. Particularly, lead compound 3S conferred 2.6‐fold higher potency than LEN against WT HIV‐1 and remained highly potent (EC50 = 5.8 nM) against the M66I mutant, a drastically advanced activity profile over LEN (EC50 > 15 µM). The unprecedented potency of our lead 3S against M66I was corroborated by a thermal shift assay. In a head‑to‑head intravenous (IV) PK study in rats, lead 3S demonstrated superior systemic exposure, showing a 4.6‑fold greater plasma area‐under‐curve (AUC) than LEN and largely retaining the long PK characteristic of LEN. These results strongly validate our design and represent a breakthrough in LEN‐based HIV‐1 therapy and prophylaxis.
Keywords: HIV‐1, capsid, lenacapavir, M66I, resistance
Lenacapavir, the first‐in‐class drug targeting HIV‐1 capsid, is a breakthrough drug in HIV‐1 treatment and prophylaxis. However, a single M66I mutation confers complete viral resistance to lenacapavir. We report herein the design and synthesis of innovative R 2 analogs demonstrating low nM potency against HIV‐1 M66I and excellent pharmacokinetics in rats.

1. Introduction
HIV capsid protein (CA) plays a few essential roles in the viral infection cycle: in the early stages, it facilitates cytoplasmic trafficking [1], reverse transcription [2, 3], nuclear import [4], uncoating [5], and integration targeting [6], regulated by various CA‐host interactions [7, 8]; in the late stages, newly produced CA assembles into the viral core consisting of approximately 250 hexamers and exactly 12 pentamers [9, 10], enabled by the protein–protein interactions between CAs [11]. HIV CA as a drug target [12] has been clinically validated by the development [13, 14] and FDA approval of lenacapavir (LEN), a long‐acting injectable (LAI) administered twice a year. Approved as a therapeutic [15] and for pre‐exposure prophylaxis (PrEP) [16], LEN could fundamentally alter the paradigm of HIV clinical management and possibly end the pandemic. However, resistance‐associated mutations (RAMs) have emerged in LEN‐treated populations [17, 18, 19], of which the major single mutations include Q67H (low fold‐resistance, FR), N74D (intermediate FR), and M66I (very high FR) [19].
In particular, the M66I mutation is most prevalent and confers complete resistance to LEN (FR > 80 000, typically no significant antiviral activity at 10 µM) [20, 21, 22]. In addition, LEN does not produce stable binding to CA M66I in biophysical experiments [22], and the LEN‐bound M66I CA structure is unattainable. Surprisingly, although the M66I mutation substantially reduces the replication capacity of HIV, it is still selected in patients alone or in combination with other mutations, whereby the viral fitness is significantly restored [19, 23]. Mitigating the M66I mutation by designing and synthesizing novel LEN analogs is highly coveted, yet second‐generation CA‐targeting drugs with retained potency against the M66I variant remain elusive. In a recent report [20], KFA‐027, an R 2 defluorinated analog (R 2 = Ph) of LEN (R 2 = di‐F Ph), exhibited slightly reduced (threefold) potency against WT HIV and sub‐µM potency against the M66I mutant. Although the potency against M66I is a significant improvement over LEN, the structural modification is minimal, especially considering that F is a well‐known bioisostere for H [24]; and the sub‐µM potency against M66I needs improvement.
LEN‐CA structural and modeling analysis (Figure 1B) [22] showed that while the M66 (Figure 1B, left) in the WT CA interacts comfortably with the di‐F phenyl ring (R 2, subunit B) of LEN, I66 (Figure 1B, right) is predicted to create significant steric clashes via β‐branching to severely hamper LEN binding. Concurrent with the reported efforts (Figure 1), we have designed and synthesized subunit B/R 2 analogs where the di‐F phenyl ring of LEN is replaced by a cycloalkyl group (Figure 1C). Structurally, these new analogs feature a non‐flat [25] R 2 moiety with reduced size, increased saturation [26], dimensionality, and conformational flexibility. Remarkably, with these structural features, the resulting analog 3S produced overwhelmingly superior antiviral and target‐binding profiles over LEN against the M66I mutant, while also demonstrating 2.6‐fold more potency than LEN against WT HIV‐1. In stark contrast, the diastereomeric 3R was less active by a few orders of magnitude, confirming the importance of stereochemistry on target binding.
FIGURE 1.

Our design of R2 analogs. (A) Structure of LEN; (B) mechanism of M66I resistance: LEN R 2 interacts with WT CA at an optimal distance (left), whereas β‐branching of I66 is predicted to induce steric hindrance (right) to impede binding. Reproduced from Briganti, L. et al. [22] (C) novel analogs featuring a cycloalkyl R 2 with reduced size, increased dimensionality, and conformational flexibility as compared to the flat di‐F phenyl of LEN.
2. Results and Discussion
2.1. Chemical Synthesis
The overall synthetic strategy for our newly designed analogs entails a modular synthesis, combining three subunits named A, B, and C (Figure 2). Subunits A and C are the same as those used for LEN, whereas structural changes (i2 group) are pursued within subunit B. The effective synthesis of our analogs requires developing a convenient procedure for subunit B. For subunit A, while reported procedures used a Simmons–Smith cyclopropanation starting with 3‐cyclopentenol [21, 27], the same preparation is not efficient for our scale‐up synthesis and does not allow control of the stereochemistry of the newly formed cyclopropane ring. Thus, a new procedure starting with (R)‐epichlorohydrin is used in our synthesis. Subunit C is synthesized based on reported procedures [21].
FIGURE 2.

Retrosynthesis of LEN analogs based on a modular synthesis.
Our synthesis of subunit A followed a procedure [28] for all steps except for d, e, and l (Scheme 1). This procedure uses the stereochemistry of the (R)‐epichlorohydrin (5) to obtain the enantiomerically pure subunit A. In the real synthetic event, (R)‐epichlorohydrin (5) reacted with allylmagnesium chloride to give epoxide 7 under basic conditions via alcohol 6. The subsequent use of lithium 2,2,6,6‐tetramethylpiperidide (LTMP) generated in situ induces an intramolecular cyclopropanation of the terminal epoxide of 7 [29, 30], providing compound 8. Oxidation of 8 with DMP led to 9, which was then transformed into 10 using isoamyl nitrite and TMSCl. At this step, the enantiopurity was verified by chiral HPLC, where only one peak was observed on the chromatogram, with a 99% purity (see Supporting Information). The carbonyl was then protected as a dithiane 11. The oxime group was then reconverted into carbonyl 12, which was deprotonated to react with ethyl trifluoroacetate (ETFA), affording 1,3‐dione 13. This 1,3‐dione was converted into salt 14 with diisopropylamine. Then the pyrazole ring on 15 was formed by reacting 14 with hydrazinoacetate hydrochloride. The enantiopurity was once again checked at this step by proton NMR with Eu(tfc)3 as a chiral lanthanide shift reagent [31], and as expected, no duplication of signals was observed (see Supporting Information). The difluorination of the dithiane of 15 gave 16, which upon saponification produced subunit A (Scheme 1).
SCHEME 1.

Synthesis of Subunit Aa. aReagents and conditions: (a) Allylmagnesium chloride, THF, −30°C, 3 h; (b) KOH, MTBE, 12 h, 47% over 2 steps; (c) n‐BuLi, 2,2,6,6‐TMP, MTBE, 0°C, 4 h, 96%; (d) DMP, DCM, 0°C to rt, 12 h, 90%; (e) isoamyl nitrite, TMSCl, DCM, −30°C, 4 h, 27%; (f) 1,2‐Ethanedithiol, pTSOH, HOAc, rt, overnight, 82%; (g) pTSOH, 2‐butanone, water, 75°C, overnight, 89%; (h) LiHMDS, ETFA, THF, −10°C, 4 h; (i) DIPA, rt, 66% over 2 steps; (j) Ethyl hydrazinoacetate hydrochloride, LiCl, CH3COCl, EtOH, 55°C, 18 h, 78%; (k) DBDMH, HF‐Pyridine, DCM, −15°C, 80%; (l) LiOH, THF/MeOH, rt, 1 h, 95%.
The synthesis of subunit B invariably entailed advanced intermediates 22. For intermediate 22c featuring a cyclopentyl R2 group, the synthesis commenced with commercially available 3,6‐dibromo‐2‐methylpyridine 17 (Scheme 2A) following a reported procedure [13, 21, 32]. Dibromination of the methyl group on the pyridine ring with N‐bromosuccinimide and azobisisobutyronitrile furnished intermediate 18, which, upon hydrolysis, yielded aldehyde 19. Condensation of aldehyde 19 with (S)‐(‐)‐tert‐butanesulfinamide afforded N‐sulfinyl imine 20. Diastereoselective nucleophilic addition [30] of cyclopentylmethylmagnesium bromide 21 to imine 20 provided two separable diastereomers (22cS/22cR).
SCHEME 2.

Synthesis of Cyclopentyl Subunit B. (a) Synthesis of cyclopentyl diastereomers. (b) New general synthesis of cycloalkyl diastereomers.
aReagents and conditions: (a) NBS, AIBN, CCl4, 80°C, 12 h; (b) AgNO3, EtOH, H2O, reflux, 5 h, 49% (two steps); (c) (S)‐(‐)‐tert‐Butanesulfinamide, Cs2CO3, DCM, rt, 1 h, 77%; (d) THF, −78°C, 2 h; (e) Mg, I2, Et2O, rt to 35°C, 1.5 h; (f) SOCl2, DMF, DCM, rt, 2 h; (g) MeNHOMe.HCl, Et3N, DCM, 0°C to rt, 1 h, 70%–85% (two steps); (h) 2,5‐dibromopyridine, TMPMgCl.LiCl, THF, −20°C, 2 h, 70%–81%; (i) (S)‐(‐)‐tert‐butanesulfinamide, Ti(OEt)4, THF, 70°C, 24 h, 47%–50%; (j) NaBH4, THF, 0°C to rt, 12 h; (k) 4 M HCl (in dioxane), MeOH, rt, 3 h; (l) Boc2O, Et3N, DCM, rt, 2 h, 93%–96% (two steps); (m) 32, Pd(PPh3)2Cl2, CuI, Et3N, DMF, rt, 12 h, 50%–82%; (n) sodium methanesulfinate, Cu(OAc)2, TMEDA, iPrOAc, 20°C–40°C, 12 h, 58%.
However, synthesis of the cyclopropyl intermediate 22aS via this reported procedure was unsuccessful due to cyclopropyl ring opening during the Grignard formation [33, 34]. Consequently, we have worked out an alternative synthetic route for intermediates 22 (Scheme 2B) [35, 36, 37], which can be applied to the synthesis of all cycloalkyl analogs. The synthesis began with commercially available carboxylic acids 24a, b, d, which were converted to the corresponding Weinreb amides 25a, b, d. Subsequent treatment of Weinreb amides with 2,5‐dibromopyridine in the presence of TMPMgCl.LiCl afforded ketones 26a, b, d. Condensation of ketones with Ellman's auxiliary in the presence of titanium(IV) ethoxide furnished N‐sulfinyl imines 27a, b, d. Diastereoselective reduction of the imine with sodium borohydride [38, 39] in THF provided diastereomerically pure 22aS, bS, dS and 22aR, bR, dR, after separation.
The two methods converged in the subsequent steps. From 22aS−dS, removal of the chiral auxiliary under acidic conditions produced amines 28aS−dS, which were Boc‐protected to afford 29aS−dS. Finally, Sonogashira coupling with the methylsulfone‐bearing alkyne 32 delivered the target subunits B 30aS−dS. Following the same synthetic route, 30aR−dR were obtained starting from 28aR−dR. Importantly, single‐crystal x‐ray crystallographic analysis of amine 28aS (Scheme 2b) confirmed the S configuration at the indicated stereogenic center (see Supporting Information).
Subunit C was prepared using a reported procedure (Scheme 3) [21]. The synthesis started with the formylation of 1‐bromo‐4‐chloro‐2‐fluorobenzene (33) to give aldehyde 34. After the aldehyde was converted into nitrile 35, a regioselective cyclization with hydrazine hydrate afforded 3‐aminoindazole 36. The subsequent alkylation of N‐1 produced compound 37, which, upon palladium‐catalyzed borylation, delivered subunit C.
SCHEME 3.

Synthesis of subunit Ca.
aReagents and conditions: (a) LDA, DMF, THF, −78°C, 99%; (b) NH2OSO3H, H2O, 50°C, overnight, 80%; (c) H2NNH2•H2O, EtOH, 80°C, overnight, 27%; (d) 2,2,2‐Trifluoroethyl trifluoromethanesulfonate, Cs2CO3, DMF, 65°C, overnight, 56%; (e) B2pin2, Pd(PPh3)2Cl2, KOAc, 1,4‐dioxane, 110°C, 70%.
The assembly of subunits for the synthesis of our analogs largely followed the procedure used for LEN synthesis (Scheme 4) [21]. For the synthesis of the desired (S)‐ isomers, Suzuki coupling between subunits B (30aS−dS) and C afforded intermediates 38aS−dS, which were converted into the bis‐sulfonamides 39aS−dS upon treatment with methanesulfonyl chloride. From these steps, the presence of two atropoisomers was observed during purification and NMR analysis. Bis‐sulfonamides 39aS−dS were treated with TFA for Boc deprotection, which also removed one methane sulfonyl group, and the resulting amines were directly condensed with the acid of subunit A to give final compounds 1S–4S. All these steps were also repeated on the (R)‐enantiomers of subunit B (30aR−dR) to afford stereoisomeric final compounds 1R–4R. Similar to LEN, each final compound exists as a mixture of two atropoisomers as described below.
SCHEME 4.

Synthesis of the LEN analogs via subunits B, C, and Aa. a Reagents and conditions, all yields with R2 as cyclopentyl: (a) Pd(dppf)Cl2, K2CO3, 1,4‐dioxane/H2O, 80°C, 16 h, 67%; (b) methane sulfonylchloride, Et3N, DCM, rt, 2 h, 58%; (c) TFA, DCM, rt, 2 h, 99%; (d) Subunit A, HATU, DIPEA, DMF, rt, overnight, 37%.
The two atropoisomers are clearly discernible on HPLC as shown with compound 3S (Figure 3, top), with an atropisomeric ratio of 1:3.8 favoring fraction 2 (Figure 3). Separation of the two fractions using preparative HPLC yielded a minor atropisomer at 10.784 min and a major one at 11.781 min. However, interconversion was observed with both atropoisomers overnight post separation, per NMR analysis (Figure 3, bottom). Specifically, the separated major atropoisomer (fraction 2) reached an atropisomeric ratio of 9:1 on 1H NMR, and the minor fraction reached a ratio of 6:4, both favoring the major atropisomer (right peak on HPLC and left peak on 1H NMR, Figure 3). These analyses are consistent with LEN [21], which indicates that the atropoisomers are separable only transiently, and interconversion occurs within hours. The assignment of 3S.2 as the major atropisomer is based on LEN atropisomerism [13, 21] and the predicted similar binding poses of 3S and LEN in WT CA (Figure 4C,D).
FIGURE 3.

Atropisomerism of compound 3S. HPLC chromatogram of 3S (top) showed fractions of the two atropisomers. 1H NMR spectra (bottom) of the two HPLC‐separated fractions indicated interconversion overnight post separation. The right peak of HPLC (fraction 2) and the left peak of 1H NMR likely correspond to the energetically more favored atropisomer 3S.2, per the assignment of LEN.
FIGURE 4.

Induced‐fit docking (IFD) poses of LEN and compound 3S to a WT and M66I CA (PDB 4XFZ) structural model. IFD poses of LEN are shown in green stick‐and‐ball format; IFD poses of compound 3S are shown in cyan; the reference experimental bound structure of LEN (PDB 6V2F) is shown in pink, and key residues are shown in gray line. The proteins are shown in transparent gray cartoons. (A) Structure of LEN. (B) Structure of compound 3S. (C) IFD pose of LEN on WT CA. (D) IFD pose of analog 3S on WT CA. (E) IFD pose of LEN on M66I CA. (F) IFD pose of compound 3S on M66I CA.
2.2. Antiviral Activity Against HIV‐1
New R 2 analogs were tested for antiviral activity against both WT and mutant M66I HIV‐1 viruses, and also for cytotoxicity, in TZM‐GFP reporter cells. LEN was used as both the positive control and the benchmark. Interestingly, of the eight analogs synthesized, the four analogs (1S, 2S, 3S, 4S) conforming to the stereochemistry of LEN, all conferred sub to very low nM potencies against WT HIV‐1 (Table 1), suggesting that a cycloalkyl group at R 2 is tolerated. Specifically, in our assay analog 1S (EC50 = 0.9 nM), 2S (EC50 = 1.0 nM), and 4S (EC50 = 0.70 nM) were moderately less potent than LEN (EC50 = 0.19 nM), whereas analog 3S (EC50 = 0.073 nM) produced a potency 2.6‐fold higher than LEN. Against the M66I mutant, LEN did not confer significant potency at concentrations up to 15 µM in our assay (Table 1), whereas our analog 4S (EC50 = 203 nM) was active in the sub‐µM range comparable to the reported potency for KFA‐027 (EC50 = 444 nM, Figure 1E). Most strikingly, our analogs 1S (EC50 = 15.7 nM), 2S (EC50 = 40 nM), and 3S (EC50 = 5.8 nM) conferred unprecedented low nM EC50 values against M66I (Table 1), decisively more potent than KFA‐02722 (EC50 = 444 nM). The overall superior antiviral profile of our new analogs suggests that the increased sp 3 character [25] and conformational flexibility [40] with cycloalkyls largely mitigate the steric clashes while still maintaining excellent target interactions. Our work so far has also revealed two important structure–activity relationship (SAR) trends: (1) the stereochemistry conforming to LEN is required as the R stereoisomers (1R, 2R, 3R, 4R) produced markedly weaker potencies against WT HIV and marginal activities against M66I; (2) analogs with a smaller cyclopropyl (1S), cyclobutyl (2S), or bigger cyclohexyl (4S) are weaker than our lead cyclopentyl analog 3S, suggesting that a 5‐membered carbocycle may be the optimal size for R 2. Collectively, these results strongly validate our analog design.
TABLE 1.
Antiviral potency against WT HIV‐1 and the M66I mutant.
| Compound | EC50 a | FR d | CC50 (µM) a | |
|---|---|---|---|---|
| WT HIV‐1 (nM) | M66I HIV‐1 (nM) | |||
| 1S | 0.9 ± 0.4 | 15.7 ± 12.0 | 18 | >100 |
| 1R | 3.8 ± 0.5 | 2300 ± 200 | 605 | >100 |
| 2S | 1.0 ± 0.2 | 40 ± 7 | 40 | >100 |
| 2R | 63 ± 9 | 2300 ± 200 | 37 | >100 |
| 3S | 0.073 ± 0.03 | 5.8 ± 4.2 | 79 | >100 |
| 3R | 12.3 ± 3.5 | 4000 ± 90 | 325 | >100 |
| 4S | 0.70 ± 0.07 | 203 ± 49 | 290 | >100 |
| 4R | 70 ± 9 | >40 000 | 570 | >100 |
| LEN | 0.19 ± 0.05 b | >15 000 c | >78 000 | >100 |
In TZM‐GFP cells.
Published EC50 = 0.13 nM.
Published EC50 >10 µM.
Fold Resistance, defined as EC50 (M66I) /EC50 (WT).
2.3. Thermal Shift Assay
To further characterize these new analogs, we assessed their effect on the stability of the target protein in a thermal shift assay (TSA) [41]. Capsid‐targeting inhibitors are known to bind to CA hexamers but not CA monomers. In this assay, WT and M66I crosslinked CA hexamers were used, and a larger ΔTm indicates higher target stabilization, which correlates with binding. The thermal shift data as shown in Table 2 largely corroborate the observed antiviral potency and SAR trends: 1) in the TSA the four R stereoisomers 1R, 2R, 3R, and 4R did not affect at all either of the tested CA hexamers (Table 2); 2) analogs 1S, 2S, 3S, and to a lesser degree 4S, showed high stabilization of M66I CA hexamer whereas LEN did not; 3) compound 3S produced an overall stabilization profile superior to that of 1S, 2S, and 4S.
TABLE 2.
Thermal shift assay (TSA) measuring the effect of compound on the stability of WT and M66I HIV‐1 cross‐linked CA hexamers.
| Compound | WT ΔTm (°C) | M66I ΔTm (°C) |
|---|---|---|
| 1S | 12.3 ± 0.1 | 9.5 ± 0.1 |
| 1R | 0.07 ± 0.09 | −0.04 ± 0.07 |
| 2S | 12.7 ± 0.2 | 9.4 ± 0.0 |
| 2R | −0.07 ± 0.1 | 0.0 ± 0.0 |
| 3S | 14.1 ± 0.1 | 10.0 ± 0.2 |
| 3R | 0.0 ± 0.09 | 0.04 ± 0.07 |
| 4S | 12.2 ± 0.1 | 7.0 ± 0.1 |
| 4R | 0.07 ± 0.1 | 0.07 ± 0.1 |
| LEN | 16.1 ± 0.4 | −1.1 ± 0.4 |
2.4. Molecular Modeling
To provide computational insights into the difference in activity between LEN and the new analog 3S, we performed induced‐fit docking (IFD) calculations [42], generating WT and M66I HIV‐1 CA structural models. The starting model for both was 4XFZ, a crystal structure of the WT native full‐length CA hexamer in complex with PF74 [11]. The existing WT 4XFZ structure was prepared for molecular docking by performing the protein preparation workflow in Schrödinger as described in the Materials and Methods section in the Supporting Information. The M66I CA structural model was obtained by taking the aforementioned prepared 4XFZ structure, performing the M66I mutation on the CA, and performing another round of the protein preparation workflow. 4XFZ was used as the reference structure, opposed to 6V2F [21], of which the cognate ligand is LEN, as the 6V2F structure, when used as a receptor for molecular docking, could not distinguish and explain the difference in activity between LEN and compound 3S.
IFD poses of LEN and compound 3S on the WT CA model show little deviation from the 6V2F crystal structure, maintaining the key protein‐ligand interactions as shown in Figure 4C,D. The only difference in pose occurs in the orientation of subunit A (R 1). The conformational flexibility of subunit A is observed in both rigid docking, induced‐fit docking, and molecular dynamics simulation (results not shown), resulting in various poses with different orientations for subunit A but not for other subunits. At other orientations, ring flipped or in the opposite dihedral direction, subunit A either maintains pi–cation interaction with K70 or forms interactions with the adjacent R173 (not shown).
IFD on the M66I CA model, however, produces drastically different results. LEN does not dock in the generated M66I CA model with the protein–ligand pose and interactions observed in 6V2F, but rather in a completely misaligned pose, resulting in the loss of key interactions (Figure 4E). On the other hand, compound 3S docks to M66I CA similarly to the observed position in 6V2F, as shown in Figure 4F. Despite the slight difference in how subunit B (R 2) sits in the binding site, compound 3S maintains the canonical protein–ligand interaction observed in 6V2F. In the absence of the LEN‐bound structure of CA M66I, the IFD calculations using the 4XFZ structure provide a qualitative explanation for the difference in activity between LEN and compound 3S.
2.5. ADME Properties
The ADME properties of our analogs were evaluated in parallel with LEN. As summarized in Table 3, all analogs exhibited profiles closely aligned with LEN across aqueous solubility, plasma stability, microsomal stability, and PAMPA permeability. Each analog showed excellent stability in both human and rat plasma, with greater than 90% of the parent compound remaining after 24 h of incubation, consistent with the high plasma stability observed for LEN. Similarly, metabolic stability in human and rat liver microsomes revealed prolonged half‐lives exceeding 120 min, indicative of low intrinsic hepatic clearance. As expected, all analogs displayed extremely low aqueous solubility at pH 7.2 and poor permeability in PAMPA. Additionally, plasma protein binding for analog 3S and LEN was compared in both species (human and rats), and each showed very high binding (>99.9%). These properties, particularly the low solubility and exceptional metabolic stability, mirror the physicochemical features underlying LEN's long‐acting PK profile, in which the compound precipitates to form a slow‑release depot upon SC administration, and therefore represent desirable attributes for further development.
TABLE 3.
Solubility, permeability, and in vitro metabolic stabilities of selected compounds.
| Compd | Aqueous solubility (µmol/L) a , n = 3 |
Plasma stability t 1/2 (h), n = 3 |
Microsomal stability b t 1/2 (min), n = 3 |
PAMPA permeability Pe c (10−6 cm/s), n = 4 |
||
|---|---|---|---|---|---|---|
| Human | Rat | Human | Rat | |||
| LEN | <0.009 d | > 24 e | > 24 e | >120 f | >120 f | <0.02 g |
| 1S | 0.019 ± 0.005 | > 24 e | > 24 e | >120 f | >120 f | <0.02 g |
| 2S | <0.009 d | > 24 e | > 24 e | >120 f | >120 f | <0.02 g |
| 3S | <0.009 d | > 24 e | > 24 e | >120 f | >120 f | <0.02 g |
| 4S | <0.009 d | > 24 e | > 24 e | >120 f | >120 f | <0.02 g |
| Verapamil | 7.5 ± 0.3 | 4.34 ± 0.03 | ||||
Note: Data is presented as mean ± SD.
Aqueous solubility was determined in Dulbecco's Phosphate‐Buffered Saline (DPBS, pH 7.2).
CYP enzyme cofactor: NADPH.
Pe: The apparent permeability coefficient. High Permeability: >1.5 × 10−6 cm/s; Low Permeability: < 1.5× 10−6 cm/s.
The measured solubility of the compound was below the lower limit of quantitation (LLOQ); therefore, values are denoted as “< lower limit estimate”.
Remaining percentage was observed to be greater than 90% at the end of incubation (24 h).
Remaining percentage was observed to be greater than 90% at the end of incubation (60 min).
The measured concentration of the compound in receiver was below the lower limit of quantitation (LLOQ); therefore, permeability is determined by replacing receiver value with LLOQ and denoted as
“< lower limit estimate”.
2.6. PK in Rats
In a subsequent head‐to‐head PK study in rats (Figure 5 and Table 4), analog 3S exhibited a markedly improved systemic exposure compared with LEN, as evidenced by persistently higher plasma concentrations over 5 days and a 4.6‐fold higher AUC0‐t following the same single intravenous dosing at 1 mg/kg. Correspondingly, analog 3S showed a substantially lower volume of distribution (V d) than LEN (0.5 L/kg vs. 4 L/kg), suggesting that it remains predominantly within the vascular compartment and supports a more controlled and plasma focused disposition. Reduced tissue sequestration may enhance target engagement while limiting off‐target accumulation. Furthermore, analog 3S displayed slower clearance than LEN (0.016 L/h/kg vs. 0.06 L/h/kg). This extremely low clearance (less than 0.5% of hepatic blood flow in rats) indicates high in vivo stability and contributes to a long terminal half‑life of 22 h, consistent with a long‑acting profile. Taken together, the superior plasma exposure of analog 3S and its favorable clearance to V d relationship suggest more predictable pharmacokinetics and the potential for improved safety and dose efficiency.
FIGURE 5.

Mean plasma concentration–time profile of LEN and compound 3S in male Wistar Hannover rats following a single IV dose (1 mg/kg).
TABLE 4.
PK parameters of LEN and compound 3S in male Wistar Hannover rats following a single IV dose (1 mg/kg).
| PK parameters | LEN (IV, 1 mg/kg) | 3S (IV, 1 mg/kg) |
|---|---|---|
| t 1/2 (h) | 51 ± 8 | 22 ± 3 |
| AUC0‐t (h.nM) | 14968 ± 2343 | 68463 ± 8655 |
| AUC0‐∞ (h.nM) | 18452 ± 1935 | 70357 ± 9925 |
| MRT0‐t (h) | 42 ± 3 | 26 ± 3 |
| V d (L/kg) | 4.2 ± 0.9 | 0.49 ± 0.03 |
| Cl (L/h/kg) | 0.06 ± 0.01 | 0.016 ± 0.002 |
Note: Data are presented as mean ± SD (n = 4). t 1/2, terminal half‐life. AUC0‐t, area under the concentration–time curve from the time of dosing to the last measurable time point. AUC0‐∞, area under the concentration–time curve from the time of dosing to infinity. MRT0‐t, mean residence time from time zero to the last measurable concentration. V d, volume of distribution. Cl, clearance.
3. Conclusion
In summary, to mitigate the high‐level resistance to LEN conferred by the M66I mutation, we have designed and synthesized LEN R2 analogs showing unprecedented low nM potency against the M66I mutant, as exemplified by analog 3S (EC50 = 5.8 nM). In the thermal shift assay, our analogs produced large shifts against the M66I CA hexamer, whereas the shift with LEN was marginal, indicating high binding affinity of our analogs and corroborating the exceptional antiviral potency observed. Our analog design features cycloalkyl R 2 groups distinctive from LEN or its known analogs. Lead 3S also demonstrated a substantially improved plasma exposure profile over LEN in the rat PK studies. Overall, the results presented here validate our design and represent a major advancement in LEN‐based HIV therapy and prophylaxis.
Author Contributions
Nicolas Jamey: writing – review and editing, writing – original draft, methodology, investigation, data curation, validation, formal analysis. D. M. Nirosh Udayanga: writing – review and editing – original draft, methodology, investigation, data curation, validation, formal analysis. Roshan Katekar: methodology, data curation, investigation, validation, writing – original draft, formal analysis. Won Hee Ryu: methodology, software, data curation, investigation, validation, visualization, writing – original draft. Huanchun Zhang: validation, methodology, data curation, investigation. Wei Xie: data curation, methodology, investigation. Jiashu Xie: methodology, data curation, investigation, supervision, formal analysis, writing – original draft, validation, resources. Zhengqiang Wang: conceptualization, investigation, formal analysis, supervision, funding acquisition, project administration, resources, writing – original draft, writing – review and editing, methodology. Karen A. Kirby: methodology, data curation, investigation, validation, formal analysis, supervision, writing – review and editing. Shreya M. Ravichandran: data curation, investigation. Zachary C. Lorson: data curation, investigation. William M. Mcfadden: data curation, investigation. Xinyong Cai: data curation, investigation. Stefan G. Sarafianos: conceptualization, formal analysis, supervision, funding acquisition, project administration, resources, writing – review and editing, investigation.
Conflicts of Interest
The authors declare no conflicts of interest.
Supporting information
Supporting File 1: anie74253‐sup‐0001‐SuppMat.pdf.
Supporting File 2: anie74253‐sup‐0002‐SuppMat.zip.
Acknowledgments
This research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI120860 (to S.G.S. and Z.W.), F31AI94923 to S.M.R., and F31AI174951 to W.M.M. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. S.G.S. acknowledges the Nahmias‐Schinazi Distinguished Chair in Research. We acknowledge the Minnesota Supercomputing Institute (MSI) at the University of Minnesota for providing computing resources. We thank Dr. Victor G. Young, Jr. at the X‐ray Crystallographic Laboratory, Department of Chemistry, University of Minnesota, for the crystallographic service. The Bruker‐AXS D8 Venture diffractometer was purchased through a grant from NSF/MRI (#1229400) and the University of Minnesota.
Contributor Information
Stefan G. Sarafianos, Email: stefanos.sarafianos@emory.edu.
Zhengqiang Wang, Email: wangx472@umn.edu.
Data Availability Statement
All data associated with this study are available in the published article and its Supporting Information: materials and methods, experimental details; X‐ray crystallography data (raw data accessible from CCDC: Deposition Number 2537357); 1H NMR, 13C NMR and 19F NMR spectra, HPLC traces; PDB coordinates for induced fit docking: 6V2F_reference, IFD_4XFZ_WT_LEN, IFD_4XFZ_WT_Compound 3S, IFD_4XFZ_M66I_LEN, IFD_4XFZ_M66I_Compound 3S.
References
- 1. Zhong Z., Ning J., Boggs E. A., et al., “Cytoplasmic CPSF6 Regulates HIV‐1 Capsid Trafficking and Infection in a Cyclophilin A‐Dependent Manner,” mBio 12 (2021): e03142–20, 10.1128/mBio.03142-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Aiken C. and Rousso I., “The HIV‐1 Capsid and Reverse Transcription,” Retrovirology 18 (2021): 29, 10.1186/s12977-021-00566-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Burdick R. C. and Pathak V. K., “Efficient HIV‐1 in Vitro Reverse Transcription: Optimal Capsid Stability is Required,” Signal Transduction and Targeted Therapy 6 (2021): 13, 10.1038/s41392-020-00458-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Bejarano D. A., Peng K., Laketa V., et al., “HIV‐1 Nuclear Import in Macrophages Is Regulated by CPSF6‐Capsid Interactions at the Nuclear Pore Complex,” Elife 8 (2019): 41800, 10.7554/eLife.41800. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Gifford L. B. and Melikyan G. B., “HIV‐1 Capsid Uncoating Is a Multistep Process That Proceeds Through Defect Formation Followed by Disassembly of the Capsid Lattice,” ACS Nano 18 (2024): 2928–2947, 10.1021/acsnano.3c07678. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Engelman A. N., “HIV Capsid and Integration Targeting,” Viruses 13 (2021): 125, 10.3390/v13010125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Hiatt J., Hultquist J. F., McGregor M. J., et al., “A Functional Map of HIV‐Host Interactions in Primary Human T Cells,” Nature Communications 13 (2022): 1752, 10.1038/s41467-022-29346-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Temple J., Tripler T. N., Shen Q., and Xiong Y., “A Snapshot of HIV‐1 Capsid–host Interactions,” Current Research in Structural Biology 2 (2020): 222–228, 10.1016/j.crstbi.2020.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Freed E. O., “HIV‐1 Assembly, Release and Maturation,” Nature Reviews Microbiology 13 (2015): 484–496, 10.1038/nrmicro3490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Sumner C. and Ono A., “The “Basics” of HIV‐1 Assembly,” Plos Pathogens 20 (2024): e1011937, 10.1371/journal.ppat.1011937. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Gres A. T., Kirby K. A., KewalRamani V. N., Tanner J. J., Pornillos O., and Sarafianos S. G., “X‐Ray Crystal Structures of Native HIV‐1 Capsid Protein Reveal Conformational Variability,” Science 349 (2015): 99–103, 10.1126/science.aaa5936. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Blair W. S., Pickford C., Irving S. L., et al., “HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention,” Plos Pathogens 6 (2010): e1001220, 10.1371/journal.ppat.1001220. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Canales E., Tse W., Schroeder S. D., et al., “Discovery of Lenacapavir: First‐in‐Class Twice‐Yearly Capsid Inhibitor for HIV‐1 Treatment and Pre‐Exposure Prophylaxis,” Journal of Medicinal Chemistry 68 (2025): 21072–21094, 10.1021/acs.jmedchem.5c01625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Link J. O., Rhee M. S., Tse W. C., et al., “Clinical Targeting of HIV Capsid Protein With a Long‐Acting Small Molecule,” Nature (London, U K) 584 (2020): 614–618, 10.1038/s41586-020-2443-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Mullard A., “FDA Approves First‐in‐Class HIV Capsid Inhibitor,” Nature Reviews Drug Discovery 22 (2023): 90. [DOI] [PubMed] [Google Scholar]
- 16. Mullard A., “FDA Approves Twice‐Yearly Capsid Inhibitor for HIV Prevention,” Nature Reviews Drug Discovery 24 (2025): 577. [DOI] [PubMed] [Google Scholar]
- 17. Margot N. A., Jogiraju V., Pennetzdorfer N., et al., “Resistance Analyses in Heavily Treatment‐Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years,” Journal of Infectious Diseases 231 (2025): 1239–1245, 10.1093/infdis/jiaf050. [DOI] [PubMed] [Google Scholar]
- 18. Naik V., Nekkalapudi A., Boopathy A. V., Falkard B., Callebaut C., and Margot N. A., “Emergence of In‐Vitro Resistance to Lenacapavir is Similar Across HIV‐1 Subtypes,” AIDS 39 (2025): 1878–1886.PMID: 40965168. [DOI] [PubMed] [Google Scholar]
- 19. van Zyl G., Prochazka M., Schmidt H.‐M. A., et al., “Lenacapavir‐Associated Drug Resistance: Implications for Scaling up Long‐Acting HIV Pre‐Exposure Prophylaxis,” Lancet HIV 12 (2025): e732–e736. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Adu‐Ampratwum D., Annamalai A. S., Dinh T., et al., “Delineating Structural Functionalities of Lenacapavir Amenable to Modifications for Targeting Emerging Drug‐Resistant HIV‐1 Capsid Variants,” Acs Medicinal Chemistry Letters 16 (2025): 2007–2014, 10.1021/acsmedchemlett.5c00405. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Bester S. M., Wei G., Zhao H., et al., “Structural and Mechanistic Bases for a Potent HIV‐1 Capsid Inhibitor,” Science 370 (2020): 360–364, 10.1126/science.abb4808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Briganti L., Annamalai A. S., Bester S. M., et al., “Structural and Mechanistic Bases for Resistance of the M66I Capsid Variant to Lenacapavir,” mBio 16 (2025): e03613–03624, 10.1128/mbio.03613-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Pennetzdorfer N., Naik V., Demirdjian S., et al., “Lenacapavir Treatment–Emergent HIV‐1 Capsid Resistance Mutations are Frequently Associated With Replication Defects,” Science Translational Medicine 18 (2026): eaea0947, 10.1126/scitranslmed.aea0947. [DOI] [PubMed] [Google Scholar]
- 24. Meanwell N. A., “Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design,” Journal of Medicinal Chemistry 54 (2011): 2529–2591, 10.1021/jm1013693. [DOI] [PubMed] [Google Scholar]
- 25. Lovering F., Bikker J., and Humblet C., “Escape From Flatland: Increasing Saturation as an Approach to Improving Clinical Success,” Journal of Medicinal Chemistry 52 (2009): 6752–6756, 10.1021/jm901241e. [DOI] [PubMed] [Google Scholar]
- 26. Liu D.‐H., Pflüger P. M., Outlaw A., et al., “Late‐Stage Saturation of Drug Molecules,” Journal of the American Chemical Society 146 (2024): 11866–11875, 10.1021/jacs.4c00807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Gillis E. P., Parcella K., Bowsher M., et al., “Potent Long‐Acting Inhibitors Targeting the HIV‐1 Capsid Based on a Versatile Quinazolin‐4‐One Scaffold,” Journal of Medicinal Chemistry 66 (2023): 1941–1954, 10.1021/acs.jmedchem.2c01732. [DOI] [PubMed] [Google Scholar]
- 28. Kadunce N., St‐Jean O., Cagulada A., et al., “Synthetic Development and Scale‐Up of a Complex Pyrazole Fragment of Lenacapavir,” Organic Process Research & Development 28 (2024): 3368–3381, 10.1021/acs.oprd.4c00235. [DOI] [Google Scholar]
- 29. Hodgson D. M., Chung Y. K., Nuzzo I., et al., “Intramolecular Cyclopropanation of Unsaturated Terminal Epoxides and Chlorohydrins,” Journal of the American Chemical Society 129 (2007): 4456–4462, 10.1021/ja0672932. [DOI] [PubMed] [Google Scholar]
- 30. Hodgson D. M., Chung Y. K., and Paris J.‐M., “Intramolecular Cyclopropanation of Unsaturated Terminal Epoxides,” Journal of the American Chemical Society 126 (2004): 8664–8665, 10.1021/ja047346k. [DOI] [PubMed] [Google Scholar]
- 31. McCreary M. D., Lewis D. W., Wernick D. L., and Whitesides G. M., “Determination of Enantiomeric Purity Using Chiral Lanthanide Shift Reagents,” Journal of the American Chemical Society 96 (1974): 1038–1054, 10.1021/ja00811a016. [DOI] [Google Scholar]
- 32. Akther T., McFadden W. M., Zhang H., Kirby K. A., Sarafianos S. G., and Wang Z., “Design and Synthesis of New GS‐6207 Subtypes for Targeting HIV‐1 Capsid Protein,” International Journal of Molecular Sciences 25 (2024): 3734, 10.3390/ijms25073734. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Künding E. P. and Perret C., “Low Temperature Grignard Reactions With Pure Mg Slurries. Trapping of Cyclopropylmethyl and Benzocyclobutenylmethyl Grignard reagents with CO2 ,” Helvetica Chimica Acta 64 (1981): 2606–2613. [Google Scholar]
- 34. Patel D. J., Hamilton C. L., and Roberts J. D., “Small‐Ring Compounds. XLIV. Interconversion of Cyclopropylcarbinyl and Allylcarbinyl Grignard Reagents 1,” Journal of the American Chemical Society 87 (1965): 5144–5148, 10.1021/ja00950a029. [DOI] [Google Scholar]
- 35. Calow A. D. J., Dailler D., and Bower J. F., “Carbonylative N‐Heterocyclization via Nitrogen‐Directed C–C Bond Activation of Nonactivated Cyclopropanes,” Journal of the American Chemical Society 144 (2022): 11069–11074, 10.1021/jacs.2c02921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Caravez J. C., Hu Y., Oftadeh E., Mamo K. T., and Lipshutz B. H., “Preparation of a Key Intermediate en Route to the Anti‐HIV Drug Lenacapavir,” Journal of Organic Chemistry 89 (2024): 3995–4000, 10.1021/acs.joc.3c02855. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Shinde A. H., Sayini R., Singh P., et al., “A New Synthesis of Enantiopure Amine Fragment: An Important Intermediate to the Anti‐HIV Drug Lenacapavir,” Journal of Organic Chemistry 90 (2025): 471–478, 10.1021/acs.joc.4c02380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Chelucci G., Baldino S., Chessa S., Pinna G. A., and Soccolini F., “An Easy Route to Optically Active 1‐Substituted‐1‐Pyridyl‐Methylamines by Diastereoselective Reduction of Enantiopure N‐tert‐Butanesulfinyl Ketimines,” Tetrahedron: Asymmetry 17 (2006): 3163–3169, 10.1016/j.tetasy.2006.11.026. [DOI] [Google Scholar]
- 39. Colyer J. T., Andersen N. G., Tedrow J. S., Soukup T. S., and Faul M. M., “Reversal of Diastereofacial Selectivity in Hydride Reductions of N—tert‐Butanesulfinyl Imines,” Journal of Organic Chemistry 71 (2006): 6859–6862, 10.1021/jo0609834. [DOI] [PubMed] [Google Scholar]
- 40. Caron G., Digiesi V., Solaro S., and Ermondi G., “Flexibility in Early Drug Discovery: Focus on the Beyond‐Rule‐of‐5 Chemical Space,” Drug Discovery Today 25 (2020): 621–627, 10.1016/j.drudis.2020.01.012. [DOI] [PubMed] [Google Scholar]
- 41. Khan M. F., Rahman M. M., Xin Y., et al., “Determination of Protein–Ligand Binding Affinities by Thermal Shift Assay,” ACS Pharmacology & Translational Science 7 (2024): 3096–3107, 10.1021/acsptsci.4c00293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Sherman W., Day T., Jacobson M. P., Friesner R. A., and Farid R., “Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects,” Journal of Medicinal Chemistry 49 (2006): 534–553, 10.1021/jm050540c. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supporting File 1: anie74253‐sup‐0001‐SuppMat.pdf.
Supporting File 2: anie74253‐sup‐0002‐SuppMat.zip.
Data Availability Statement
All data associated with this study are available in the published article and its Supporting Information: materials and methods, experimental details; X‐ray crystallography data (raw data accessible from CCDC: Deposition Number 2537357); 1H NMR, 13C NMR and 19F NMR spectra, HPLC traces; PDB coordinates for induced fit docking: 6V2F_reference, IFD_4XFZ_WT_LEN, IFD_4XFZ_WT_Compound 3S, IFD_4XFZ_M66I_LEN, IFD_4XFZ_M66I_Compound 3S.
